Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! AI is eating the world—and the machines behind it are ravenous. Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink. Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and b ...

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! AI is eating the world—and the machines behind it are ravenous. Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink. Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and b ...

We recently compiled a list of the 12 Cheap Small-Cap Stocks to Invest In Before the Next Breakout.  STAAR Surgical Company tops our list for being one of the best small-cap stocks on our list. TheFly reported on January 16 that Morgan Stanley resumed coverage of STAA with an Underweight rating and a $13 price target following the termination of its merger agreement with Alcon (ALC). The firm described STAAR’s EVO ICL technology as “impressive” but noted it remains a niche product with a limited addressab ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: STAAR Surgical’s CEO is stepping down after the implantable eye lens manufacturer opposed a $1.6 billion takeover. Encouraged by activist investor Broadwood Partners, STAAR shareholders rejected Alcon’s $1.6 billion offer last week. Thursday, STAAR revealed a cooperation agreement with Broadwood that has reshaped its board. Stephen Farrell has left th ...

STAAR Surgical Company (NASDAQ:STAA) shares are down on Thursday as the company is undergoing significant board changes.Broadwood Partners Joins STAAR Surgical BoardNeal Bradsher and Richard LeBuhn of Broadwood Partners, along with Christopher Wang of Yunqi Capital, have joined STAAR's Board of Directors following a cooperation agreement.This change also sees the departure of Chair Elizabeth Yeu and CEO Stephen Farrell, who will remain in his role until January 31, 2026.The board's restructuring aims to enh ...

GENEVA--(BUSINESS WIRE)--Alcon Terminates Agreement to Acquire STAAR Surgical. ...

STAAR Surgical Company (NASDAQ:STAA) announced Tuesday that it did not receive the necessary stockholder votes to approve the merger agreement with Alcon Inc. (NYSE:ALC) at the Special Meeting of Stockholders.STAAR intends to terminate its merger agreement with Alcon.No termination fee will be payable by either party, and STAAR will remain a standalone publicly traded company.Stephen Farrell, CEO of STAAR, said, “…In the short term, we will continue to prioritize profitable sales growth while we drive effic ...

NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates ("Broadwood†or "we†), which together own 30.2% of the outstanding common stock of STAAR Surgical Company ("STAAR†or the "Company†) (NASDAQ: STAA), commented on the results of the Special Meeting of Shareholders (the "Special Meeting†) that was held earlier today in connection with the proposed acquisition of STAAR by Alcon Inc. ("Alcon†) (NYSE: ALC). Based on preliminary results, shareholders voted decisively to reject the. ...

Core Viewpoint - STAAR Surgical plans to terminate its merger agreement with Alcon due to insufficient shareholder votes for approval, resulting in a decline in its share price [1] Company Summary - STAAR Surgical is ending its merger agreement with Swiss eyecare company Alcon after failing to secure the necessary shareholder votes [1] - The announcement has led to a decrease in STAAR Surgical's share price [1] Industry Summary - The eyecare industry is experiencing significant changes as merger agreements face challenges in gaining shareholder approval, impacting company valuations and market dynamics [1]

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) ("STAAR†), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, announced that based on preliminary estimates by STAAR's proxy solicitor, STAAR did not receive the necessary stockholder votes to approve the merger agreement with Alcon at the Special Meeting of Stockholders held today. STAAR intends to terminate its merger agreement with Alcon. No termination fee wil ...